echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine's new generation of PARP inhibitor fluzoparib (Irei®) is included in the new version of the National Medical Insurance Catalogue in 2021

    Hengrui Medicine's new generation of PARP inhibitor fluzoparib (Irei®) is included in the new version of the National Medical Insurance Catalogue in 2021

    • Last Update: 2021-12-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 3, 2021, the National Medical Insurance Administration and the Ministry of Human Resources and Social Security officially announced the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021)"


    Source: National Medical Security Administration official website

    Ovarian cancer is one of the common malignant tumors in women, and 70% of ovarian cancers are at an advanced stage when they are discovered


    In recent years, many studies have shown that PARP inhibitors for platinum-sensitive recurrent ovarian cancer can effectively delay the recurrence of ovarian cancer and improve the overall survival of patients


    Maintenance treatment with PARP inhibitors needs to last for 2-3 years.


    Fluzoparib, which has entered the new version of the National Medical Insurance Catalogue this time, is a new type of Chinese original PARP inhibitor


    Fluzoparib maintenance treatment can significantly prolong the progression-free survival of patients with platinum-sensitive recurrent ovarian cancer and reduce the risk of recurrence or death by 75%

    At present, the FZOCUS-1 study exploring fluzoparib combined with apatinib for maintenance treatment of advanced ovarian cancer after first-line platinum-containing chemotherapy is underway


    Reference materials:

    [1] Gao Qinglei et al.


    [2] "Progress in Standardized Surgical Treatment of Ovarian Cancer" Yao Xin

    [3] "[Fluoride comes to the top, another great achievement] Ovarian Cancer Frontier Forum and Fluzoparibum Sensitive Recurrence Maintenance Therapy Indications Market Meeting Successfully Held" China Medical Tribune Oncology Today

    [4] "Chinese Expert Consensus on the Management of Adverse Reactions of PARP Inhibitors (2021 Edition)"

    [5] Official Weibo of Hengrui Pharmaceuticals: "New Breakthrough! The second indication of Hengrui Pharmaceutical's innovative drug fluzoparib was approved for marketing.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.